Publications by authors named "Bruno Tegel"
Analysis of Tumor Burden as a Biomarker for Patient Survival with Neuroendocrine Tumor Liver Metastases Undergoing Intra-Arterial Therapies: A Single-Center Retrospective Analysis.
Cardiovasc Intervent Radiol
October 2022
Article Synopsis
- The study evaluates the effectiveness of using quantitative MRI analysis of tumor burden in predicting survival for patients with neuroendocrine tumor liver metastases undergoing specific intra-arterial therapies.
- A total of 122 patients were analyzed, with measurements taken from their largest liver lesions and categorized into low and high tumor burden groups.
- Results showed that lower tumor burdens significantly correlated with longer median overall survival, indicating that these measurements are critical prognostic factors for patient outcomes.
Background: The prognosis of patients with renal cell carcinoma (RCC) depends greatly on the presence of extra-renal metastases.
Purpose: To investigate the value of total tumor volume (TTV) and enhancing tumor volume (ETV) as three-dimensional (3D) quantitative imaging biomarkers for disease aggressiveness in patients with RCC.
Material And Methods: Retrospective, HIPAA-compliant, IRB-approved study including 37 patients with RCC treated with image-guided thermal ablation during 2007-2015.
Lipiodol as an Imaging Biomarker of Tumor Response After Conventional Transarterial Chemoembolization: Prospective Clinical Validation in Patients with Primary and Secondary Liver Cancer.
Transl Oncol
March 2020
Background/aim: Treatment of patients with large hepatocellular carcinoma (HCC) remains challenging and survival in advanced tumor stages is limited. This study was conducted to investigate the efficacy of embolization followed by computed tomography (CT)-guided interstitial high-dose-rate brachytherapy (CT-HDRBT) in patients with unresectable HCC.
Patients And Methods: A total of 47 patients undergoing CT-HDRBT were divided into 2 groups: i) patients previously treated with transarterial chemoembolization (TACE) and ii) patients treated with bland transarterial embolization (TAE).